- Trials with a EudraCT protocol (555)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
555 result(s) found for: Biological activity.
Displaying page 7 of 28.
EudraCT Number: 2010-023677-19 | Sponsor Protocol Number: VITAD-2010 | Start Date*: 2011-03-23 | |||||||||||
Sponsor Name:AZIENDA OSPEDALIERA S. LUIGI GONZAGA | |||||||||||||
Full Title: Bio-molecular effects of interferon-beta and d-vitamin association | |||||||||||||
Medical condition: PATIENT WITH RRMS AND SPMS | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2020-001823-15 | Sponsor Protocol Number: 20CH089 | Start Date*: 2020-04-28 | ||||||||||||||||
Sponsor Name:CHU de Saint Etienne | ||||||||||||||||||
Full Title: Evaluation of the concentration-effect relationship of enoxaparin for thromboembolic prevention in COVID-19 resuscitation patients. COV-ENOX study | ||||||||||||||||||
Medical condition: covid-19 | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: FR (Ongoing) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-003680-38 | Sponsor Protocol Number: HDVitC | Start Date*: 2015-06-12 |
Sponsor Name:VU university medical center | ||
Full Title: Pharmacokinetics of two different high dose regimes of intravenous vitamin C in critically ill patients | ||
Medical condition: Critically ill patients with trauma or sepsis exhibit a high degree of vitamin C deficiency at ICU admission and vitamin C plasma concentrations decrease even more during the first three days of ad... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2016-001170-15 | Sponsor Protocol Number: CECUM | Start Date*: 2017-10-19 |
Sponsor Name:GETECCU (Grupo Español de Trabajo en Enfermedad de Crohn y Colitis ulcerosa) | ||
Full Title: Efficacy of high-dose corticosteroid pulses added to conventional oral corticosteroid course in comparison with monotherapy oral corticosteroid course for moderate flares of ulcerative colitis: a... | ||
Medical condition: Moderate flares of Ulcerative Colitis | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2009-011251-48 | Sponsor Protocol Number: CNTO888PCR2001 | Start Date*: 2009-08-28 | |||||||||||
Sponsor Name:Janssen Biologics B.V. | |||||||||||||
Full Title: An Open-label, Multicenter, Phase 2 Study of Single-agent CNTO 888 (an anti-CCL2 Monoclonal Antibody) for the Treatment of Subjects with Metastatic Castrate-Resistant Prostate Cancer | |||||||||||||
Medical condition: Metastatic Castrate-Resistant Prostate Cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) BE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-000563-41 | Sponsor Protocol Number: IMIMFTCL/GH/4 | Start Date*: 2014-08-08 |
Sponsor Name:Consorci Mar Parc de Salut de Barcelona (Parc de Salut Mar) | ||
Full Title: Recombinant hGH Biomarkers Discovery | ||
Medical condition: Healthy volunteers. There is not intended indication. | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2010-018900-10 | Sponsor Protocol Number: FLIP110 | Start Date*: 2010-05-11 | |||||||||||
Sponsor Name:Laboratoires Mayoly Spindler | |||||||||||||
Full Title: Safety and preliminary clinical activity of Yarrowia lipolytica lipase (MS1819) in patients with malabsorption syndrome due to exocrine pancreatic insufficiency resulting from chronic pancreatitis | |||||||||||||
Medical condition: Exocrine pancreatic insufficiency resulting from chronic pancreatitis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-001727-12 | Sponsor Protocol Number: TPV11 | Start Date*: 2019-10-24 | |||||||||||
Sponsor Name:Topas Therapeutics GmbH | |||||||||||||
Full Title: A multi-centre, open-label, phase 1 study, Part A single ascending dose and Part B multiple dose, to evaluate the safety, tolerability and pharmacokinetics, and to explore early signs of effectiven... | |||||||||||||
Medical condition: Pemphigus vulgaris | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-003138-17 | Sponsor Protocol Number: P1200_51 | Start Date*: 2020-01-17 | |||||||||||
Sponsor Name:Cliniques universitaires Saint-Luc | |||||||||||||
Full Title: A 24 weeks proof of concept study to evaluate the clinical, MRI and synovial tissue benefit of Sarilumab in active RA patients despite TNF agents | |||||||||||||
Medical condition: Medical condition – Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-000666-10 | Sponsor Protocol Number: m16-063 | Start Date*: 2018-12-17 | |||||||||||
Sponsor Name:AbbVie Deutschland GmbH & Co. KG | |||||||||||||
Full Title: A Phase 2 Study to Investigate the Safety and Efficacy of ABBV-105 Given Alone or in Combination with Upadacitinib (ABBV-599 Combination) with a Background of Conventional Synthetic DMARDs in Subje... | |||||||||||||
Medical condition: Rheumatoid Arthritis | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) HU (Completed) BE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-001753-17 | Sponsor Protocol Number: ATYR1940-C-002 | Start Date*: 2014-09-19 | |||||||||||
Sponsor Name:aTyr Pharma, Inc. | |||||||||||||
Full Title: A Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Biological Activity of ATYR1940 in Adult Patients with Molecularly Define... | |||||||||||||
Medical condition: Facioscapulohumeral muscular dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Completed) IT (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-001350-21 | Sponsor Protocol Number: APL2-PNH-209 | Start Date*: 2020-12-08 | |||||||||||
Sponsor Name:Apellis Pharmaceuticals, Inc. | |||||||||||||
Full Title: An Open-Label, Single-Arm, Phase 2 Study to Evaluate the Safety, Pharmacokinetics, and Biologic Activity of Pegcetacoplan in Pediatric Patients with Paroxysmal Nocturnal Hemoglobinuria | |||||||||||||
Medical condition: Paroxysmal Nocturnal Hemoglobinuria | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: CZ (Prematurely Ended) NL (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2017-002026-20 | Sponsor Protocol Number: CT7001-001 | Start Date*: 2017-10-31 |
Sponsor Name:Carrick Therapeutics | ||
Full Title: A Modular, Multipart, Multiarm, Open-label, Phase I/IIa Study to Evaluate the Safety and Tolerability of CT7001 Alone and in Combination with Anti-cancer Treatments in Patients with Advanced Malign... | ||
Medical condition: Module 1A: All solid malignancies Module 1B: Solid malignancies, potentially including TNBC, SCLC, CRPC, ovarian cancer patients, and other appropriate cancer indications. Module 1B-1 (TNBC):... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2011-006198-25 | Sponsor Protocol Number: HE7/12 | Start Date*: 2012-10-24 | |||||||||||
Sponsor Name:Hellenic Cooperative Oncology Group | |||||||||||||
Full Title: A Phase II, single-arm clinical trial of administration of cisplatin and 5-fluorouracil with afatinib as first-line therapy in patients with inoperable gastric or gastroesophageal junction cancer | |||||||||||||
Medical condition: Inoperable gastric and gastroesophageal junction cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001912-36 | Sponsor Protocol Number: ATYR1940-C-005 | Start Date*: 2015-08-04 | |||||||||||
Sponsor Name:aTyr Pharma, Inc. | |||||||||||||
Full Title: An Open-Label Extension Study to Evaluate the Long-Term Safety, Tolerability, Biological Activity, and Systemic Exposure of ATYR1940 in Adult Patients with Facioscapulohumeral Muscular Dystrophy (F... | |||||||||||||
Medical condition: Facioscapulohumeral muscular dystrophy | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NL (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2017-004494-13 | Sponsor Protocol Number: INT-TET1-7371 | Start Date*: 2018-04-09 | |||||||||||
Sponsor Name:FONDAZIONE IRCCS "ISTITUTO NAZIONALE DEI TUMORI" | |||||||||||||
Full Title: IMPROVING TREATMENT STRATEGIES IN THYMIC EPITHELIAL TUMORS: A TYME COLLABORATIVE EFFORT | |||||||||||||
Medical condition: Patients diagnosed with thymic carcinoma / thymoma B3 with areas of carcinoma with metastatic or relapsed non-pre-treated disease. | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Prematurely Ended) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2019-002514-40 | Sponsor Protocol Number: CISTA-TB | Start Date*: 2019-10-31 | |||||||||||
Sponsor Name:ISTITUTO NAZIONALE PER LE MALATTIE INFETTIVE "LAZZARO SPALLANZANI" | |||||||||||||
Full Title: Phase II study on the safety and efficacy of cysteamine in association with standard tuberculosis therapy for the treatment of patients with pulmonary tuberculosis: a new therapy for tuberculosis d... | |||||||||||||
Medical condition: Pulmonary Mycobacterium tuberculosis infection | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Trial now transitioned) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2014-002008-25 | Sponsor Protocol Number: 4053-101 | Start Date*: 2014-09-10 | |||||||||||
Sponsor Name:Sarepta Therapeutics, Inc. | |||||||||||||
Full Title: A 2-Part, Randomized, Double-Blind, Placebo-Controlled, Dose Titration, Safety, Tolerability, and Pharmacokinetics Study (Part 1) Followed by an Open-Label Efficacy and Safety Evaluation (Part 2) o... | |||||||||||||
Medical condition: Patients with Duchenne Muscular Dystrophy Amenable to Exon 53 Skipping | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) IT (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-001526-27 | Sponsor Protocol Number: STH14707 | Start Date*: 2007-06-19 | |||||||||||
Sponsor Name:Sheffield Teaching Hospitals NHS Foundation Trust | |||||||||||||
Full Title: ANZAC: A Randomised Phase II Feasibility Study Investigating The Biological Effects of the Addition of Zoledronic Acid To Neoadjuvant Comnination Chemotherapy On Invasive Breast Cancer | |||||||||||||
Medical condition: Breast cancer | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-005568-14 | Sponsor Protocol Number: V72_60 | Start Date*: 2015-06-08 |
Sponsor Name:Novartis Pharma Services A.G. | ||
Full Title: A Phase 3, Open Label, Randomized, Controlled, Multi-Center Study to Evaluate the Safety and Immunogenicity of Novartis Meningococcal B Recombinant Vaccine When Administered Concomitantly With Rout... | ||
Medical condition: Prophylaxis of meningococcal meningitiditis caused by Neisseria meningitidis bacterium, serogroup B | ||
Disease: | ||
Population Age: Infants and toddlers, Under 18 | Gender: Male, Female | |
Trial protocol: Outside EU/EEA | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
